ING Groep NV Acquires New Shares in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

ING Groep NV acquired a new position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 12,500 shares of the biopharmaceutical company’s stock, valued at approximately $1,044,000.

A number of other institutional investors also recently bought and sold shares of ITCI. China Universal Asset Management Co. Ltd. raised its stake in shares of Intra-Cellular Therapies by 10.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 22,480 shares of the biopharmaceutical company’s stock worth $1,878,000 after buying an additional 2,157 shares during the last quarter. Barclays PLC increased its holdings in Intra-Cellular Therapies by 282.0% during the 3rd quarter. Barclays PLC now owns 34,453 shares of the biopharmaceutical company’s stock valued at $2,521,000 after acquiring an additional 25,435 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its position in Intra-Cellular Therapies by 31.9% during the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 454,538 shares of the biopharmaceutical company’s stock worth $33,258,000 after acquiring an additional 109,892 shares during the last quarter. Oak Ridge Investments LLC lifted its holdings in shares of Intra-Cellular Therapies by 74.1% in the fourth quarter. Oak Ridge Investments LLC now owns 19,831 shares of the biopharmaceutical company’s stock valued at $1,656,000 after purchasing an additional 8,440 shares in the last quarter. Finally, Cynosure Group LLC grew its position in shares of Intra-Cellular Therapies by 161.0% in the third quarter. Cynosure Group LLC now owns 14,442 shares of the biopharmaceutical company’s stock valued at $1,057,000 after purchasing an additional 8,909 shares during the last quarter. 92.33% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Intra-Cellular Therapies

In other Intra-Cellular Therapies news, CEO Sharon Mates sold 51,000 shares of the business’s stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $85.80, for a total transaction of $4,375,800.00. Following the completion of the sale, the chief executive officer now directly owns 1,070,329 shares in the company, valued at $91,834,228.20. The trade was a 4.55 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 2.60% of the company’s stock.

Intra-Cellular Therapies Stock Up 0.0 %

Shares of NASDAQ ITCI opened at $128.60 on Monday. The stock has a market capitalization of $13.67 billion, a PE ratio of -147.81 and a beta of 0.72. The firm has a fifty day moving average of $110.27 and a 200-day moving average of $89.84. Intra-Cellular Therapies, Inc. has a 52-week low of $62.78 and a 52-week high of $128.77.

Intra-Cellular Therapies (NASDAQ:ITCI) last posted its quarterly earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.08). The firm had revenue of $199.22 million for the quarter, compared to analysts’ expectations of $205.08 million. Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. Equities research analysts expect that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

ITCI has been the subject of several research reports. Leerink Partnrs downgraded Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 13th. Needham & Company LLC reissued a “hold” rating on shares of Intra-Cellular Therapies in a report on Friday. StockNews.com initiated coverage on Intra-Cellular Therapies in a research note on Monday. They set a “hold” rating on the stock. Piper Sandler reissued a “neutral” rating and issued a $132.00 target price (up previously from $107.00) on shares of Intra-Cellular Therapies in a research note on Tuesday, January 14th. Finally, JPMorgan Chase & Co. upped their target price on shares of Intra-Cellular Therapies from $81.00 to $89.00 and gave the company an “overweight” rating in a report on Monday, November 4th. Nine research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Intra-Cellular Therapies presently has a consensus rating of “Moderate Buy” and an average target price of $103.62.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.